

Thyroid cancer review questions

No.	Review question
1.1	What is the diagnostic accuracy of ultrasound for identifying thyroid nodule malignancies or nodules with malignant potential?
1.2	What is the clinical and cost effectiveness of 1) measurement of thyroid peroxidase antibody (TPO), and 2) measurement of serum calcitonin, at initial presentation?
1.3	What is clinical and cost effectiveness of radioisotope scans for people with suspected thyroid cancer?
1.4	In people with thyroid nodules on ultrasound at initial presentation, for what size and classification is it clinically and cost effective to use active surveillance or discharge rather than biopsy?
1.5	For people with thyroid nodules that require further investigation following ultrasound, what is the diagnostic accuracy of fine needle aspiration cytology (FNAC) with rapid on-site assessment, FNAC without rapid on-site assessment or core biopsy for diagnosing thyroid cancer?
1.6	For people with fine-needle aspiration samples showing benign cytology or non-diagnostic features but with US / clinical findings indicative of increased risk of malignancy, is it clinically and cost effective to use diagnostic hemithyroidectomy, repeat FNAC, use active surveillance or discharge?
1.7	For people who have had fine-needle aspiration samples, where the FNAC sample was adequate but was not able to differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing?
1.8	In people with differentiated thyroid cancer at different initial disease stages (based on prior investigations), what is the clinical and cost-effectiveness of further refinement of staging by CT (with or without contrast), MRI, PET or bone scan?
2.1	For people with differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance, hemi-thyroidectomy (with or without prophylactic or therapeutic node dissection) or total thyroidectomy (with or without prophylactic or therapeutic node dissection)?
3.1	What is the clinical and cost effectiveness of radioactive iodine with withdrawal of thyroid hormone replacement versus radioactive iodine with thyrotropin alfa?
3.1c	What is the clinical and cost effectiveness of radioactive iodine (RAI) ablation/treatment versus no RAI ablation/treatment in different population groups, characterised by stage, type of differentiated cancer, existence of vascular infiltration and gender?
3.2	What is the most clinically and cost-effective administered activity for people receiving radioactive iodine after thyroidectomy?
3.3	For people with residual, metastatic or recurrent thyroid cancer, what is the clinical and cost effectiveness of external beam radiotherapy?
3.4a	What is the clinical and cost effectiveness of TSH suppression versus no TSH suppression in different population groups, characterised by recurrence risk, ethnicity, gender and age?
3.4b	For people who have had thyroidectomy and radioactive iodine treatment for differentiated thyroid cancer, what is the most clinically and cost-effective length of treatment with drugs (such as levothyroxine) to suppress TSH to subnormal levels?

Thyroid cancer review questions

4.1	For people who have had thyroidectomy and radioactive iodine for differentiated thyroid cancer, what is the clinical and cost effectiveness of measuring thyroglobulin and thyroglobulin antibodies (with or without radioisotope scans) to assess residual or recurrent disease?
4.2	For people who have had treatment for differentiated thyroid cancer and who have undetectable thyroglobulin on standard assays, what is the clinical and cost effectiveness of using stimulated thyroglobulin or highly sensitive thyroglobulin assays, to re-assess risk of recurrence after initial treatment and to tailor their follow-up regimen?
4.3	<ol style="list-style-type: none">1. For people who have had treatment for differentiated thyroid cancer, what is the optimum frequency of follow-up according to the severity, spread of the disease and treatment given?2. For people who have had treatment for differentiated thyroid cancer, what is the optimum length of follow-up according to the severity, spread of the disease and treatment given?
5.1	What information, education and support do people with suspected and confirmed thyroid cancer and their families and carers need?